Invention Grant
![4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors](/docs/US/2020-12-01/US10851097B2/abs.jpg.600x600.jpg)
- Patent Title: 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
-
Application No.: US15772861Application Date: 2016-11-02
-
Publication No.: US10851097B2Publication Date: 2020-12-01
- Inventor: Matthew Colin Thor Fyfe
- Applicant: Topivert Pharma Limited
- Applicant Address: GB London
- Assignee: TOPIVERT PHARMA LIMITED
- Current Assignee: TOPIVERT PHARMA LIMITED
- Current Assignee Address: GB London
- Agency: Seed IP Law Group LLP
- Priority: GB1519381.6 20151103; GB1606968.4 20160421
- International Application: PCT/GB2016/053387 WO 20161102
- International Announcement: WO2017/077283 WO 20170511
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D519/00 ; A61K45/06 ; A61K31/497 ; A61K31/541
![4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors](/abs-image/US/2020/12/01/US10851097B2/abs.jpg.150x150.jpg)
Abstract:
There are provided compounds of formula (I), wherein X, Ak, s, L, Q, R1 and R2 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of the JAK family) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.
Public/Granted literature
Information query
